Sponsors Staying On Schedule With Postmarketing Requirements And Commitments
Executive Summary
About 80% of drug sponsors were on track with post approval studies in FY 2017, US Food and Drug Administration notes in its annual report on performance of applicants.
You may also be interested in...
US FDA's Postmarket Study Requirements: Industry Wants Standardization, Expert Input
PhRMA, BIO and Pfizer call for predictable process for setting postmarket commitments and requirements, periodic reevaluation of their necessity and feasibility, and FDA acceptance of novel trial designs.
Drug Sponsors Are On Schedule With Most Post-Approval Studies
US FDA's Gottlieb touts use of real world evidence as report shows vast majority of postmarketing requirements and commitments progressing on schedule.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.